

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

<b>Exchange</b>	NASDAQ CM (US Dollar)
<b>Price</b>	<b>\$2.05</b>
<b>Change (%)</b>	0.00 (0.00%)
<b>Volume</b>	0
<b>52 Week Low</b>	\$1.75
<b>Market Cap</b>	\$19,095,713
<b>Rolling EPS</b>	0.14
<b>PE Ratio</b>	14.6421
<b>Shares Outstanding</b>	9,314,982

Data as of 08/15/18 4:00 p.m. ET



## Recent Headlines & Events

08/09/18 - 8:01 a.m.  
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights

08/02/18 - 8:00 a.m.  
Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second

Date	Title
09/05/18 2:35 p.m. ET	<b>H. C. Wainwright 20th Annual Global Investment Conference</b> <b>Location</b> New York, NY

Quarter 2018 Financial Results and Recent Highlights

07/05/18 - 4:05 p.m.

Fibrocell Announces Closing of \$4.0 Million Registered Direct Offering

10/03/18  
through  
10/05/18

**Alliance for Regenerative Medicine  
- 2018 Cell & Gene Meeting on the  
Mesa**

**Location** La Jolla, CA

10/09/18

**Chardan 2nd Annual Genetic  
Medicines Conference**

**Location** New York, NY

## SEC Filings

Filing Date	Form
08/09/18	10-Q
08/09/18	8-K
08/08/18	EFFECT
07/27/18	S-1

## Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

## Ownership Summary

### Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	36	12.51	51.4	4,786,707
Mutual Fund	11	.38	1.5	139,108
Director and Officer	0	.00	0.0	0

\*Insider values reflect direct beneficial ownership.

### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	1,653,486	17.8	3	06/30/18
Sabby Management, LLC	679,408	7.3	679,408	05/29/18
Anson Funds Management LP.	679,408	7.3	679,408	05/29/18
Heights Capital Management, Inc.	679,408	7.3	679,408	05/29/18
Intracoastal Capital, L.L.C.	335,466	3.6	335,466	07/11/18
Renaissance Technologies LLC	162,281	1.7	138,742	06/30/18
MSD Partners, L.P.	138,592	1.5	0	06/30/18
The Vanguard Group, Inc.	123,991	1.3	49,262	06/30/18
CVI Holdings LLC	117,099	1.3	117,099	06/30/18
Point72 Asset Management, L.P.	80,000	0.9	0	06/30/18

Data provided by Nasdaq. Minimum 15 minutes delayed.